SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90: 766771.
  • 2
    D'Amico AV, Whittington R, Malkowicz SB, et al. The clinical utility of the percent of positive prostate biopsies in defining biochemical outcome following radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000; 18: 11641172.
  • 3
    D'Amico AV, Schultz D, Silver B, et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2001; 49: 679684.
  • 4
    Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence following radical prostatectomy. J Clin Oncol. 2002; 20: 32063212.
  • 5
    Graefen M, Karakiewicz PI, Cagiannos I, et al. A comparison of two preoperative nomograms predicting recurrence following radical prostatectomy [abstract 919.11]. J Urol. 2002; 167: 231.
  • 6
    Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease free survival. J Urol. 1996; 156: 450453.
  • 7
    Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001; 51: 3140.
  • 8
    Critz FA, Williams WH, Benton JB, Levinson AK, Holladay AC, Holladay DA. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol. 2000; 163: 10851089.
  • 9
    Vicini F, Martinez A, Hanks GE, et al. An interinstitutional and interspeciality comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer. 2002; 95: 21262135.
  • 10
    Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001; 50: 12431252.
  • 11
    Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002; 167: 112116.
  • 12
    Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 15911596.
  • 13
    Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997; 158: 14411445.
  • 14
    Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001; 76: 576581.
  • 15
    Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol. 1997; 15: 230238.
  • 16
    Sartor CI, Strawderman MH, Lin XH, Kish KE, McLaughlin PW, Sandler HM. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 1997; 38: 941947.
  • 17
    Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000; 48: 629623.
  • 18
    D'Amico AV, Cote K, Lofffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer specific survival following radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002. In press.